These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1495742)

  • 1. Accumulation of cis-diamminedichloroplatinum (II) and its analogues in sensitive and resistant human ovarian carcinoma cells.
    Misawa T; Kikkawa F; Oguchi H; Morikawa Y; Kawai M; Maeda O; Iwata M; Kano T; Furuhashi Y; Tomada Y
    Oncology; 1992; 49(3):173-9. PubMed ID: 1495742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
    Misawa T; Kikkawa F; Maeda O; Obata NH; Higashide K; Suganuma N; Tomoda Y
    Jpn J Cancer Res; 1995 Jan; 86(1):88-94. PubMed ID: 7737915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells.
    Kikkawa F; Kojima M; Oguchi H; Maeda O; Ishikawa H; Tamakoshi K; Mizuno K; Kawai M; Suganuma N; Tomoda Y
    Anticancer Res; 1993; 13(4):891-6. PubMed ID: 8352556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione related enzymes in cis-diamminedichloroplatinum (II)-sensitive and-resistant human ovarian carcinoma cells.
    Oguchi H; Kikkawa F; Kojima M; Maeda O; Mizuno K; Suganuma N; Kawai M; Tomoda Y
    Anticancer Res; 1994; 14(1A):193-200. PubMed ID: 7909418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
    Akamatsu K; Saito H; Tsunenari T; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1993; 13(6A):2261-5. PubMed ID: 8297143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and cellular accumulation of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) monohydrate, in cisplatin-sensitive and -resistant murine P388 leukemia cells.
    Kamisango K; Matsumoto T; Akamatsu K; Morikawa K; Tashiro T; Koizumi K
    Jpn J Cancer Res; 1992 Mar; 83(3):304-11. PubMed ID: 1582895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.
    Takahashi I; Maehara Y; Kusumoto H; Kohnoe S; Sugimachi K
    Cancer Chemother Pharmacol; 1993; 33(1):31-5. PubMed ID: 8269586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
    Nio Y; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
    Anticancer Res; 1991; 11(2):761-7. PubMed ID: 2064331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats.
    Akamatsu K; Endo K; Matsumoto T; Morikawa K; Koizumi M; Koizumi K; Mitsui H
    Jpn J Cancer Res; 1991 Jun; 82(6):724-31. PubMed ID: 1906857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interactions of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) and related compounds with deoxyribonucleic acid.
    Morikawa K; Matsumoto T; Matsuoka Y; Koizumi K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):212-9. PubMed ID: 1576676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells.
    Fujiwara Y; Nakamura M; Yokoo S
    Br J Cancer; 1993 Jun; 67(6):1285-92. PubMed ID: 8512813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
    Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI
    Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.
    Minagawa Y; Kigawa J; Ishihara H; Itamochi H; Terakawa N
    Jpn J Cancer Res; 1994 Sep; 85(9):966-71. PubMed ID: 7961127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
    Ma J; Maliepaard M; Kolker HJ; Verweij J; Schellens JH
    Cancer Chemother Pharmacol; 1998; 41(3):186-92. PubMed ID: 9443634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent antitumour activity of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) against advanced L1210 leukaemia in mice.
    Akamatsu K; Endo K; Matsumoto T; Kamisango K; Morikawa K; Koizumi M; Koizumi K
    Br J Cancer; 1992 Nov; 66(5):827-32. PubMed ID: 1419625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
    Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells.
    Kikuchi Y; Iwano I; Miyauchi M; Kita T; Sugita M; Tenjin Y; Nagata I
    Jpn J Cancer Res; 1990; 81(6-7):701-6. PubMed ID: 2119370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.